WINTON GROUP Ltd Has $262,000 Position in Sotera Health (NASDAQ:SHC)

WINTON GROUP Ltd reduced its stake in Sotera Health (NASDAQ:SHC) by 65.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 22,106 shares of the company’s stock after selling 41,452 shares during the quarter. WINTON GROUP Ltd’s holdings in Sotera Health were worth $262,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. William Blair Investment Management LLC lifted its holdings in Sotera Health by 0.6% in the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company’s stock worth $13,430,000 after purchasing an additional 6,707 shares during the last quarter. Texas Permanent School Fund Corp lifted its holdings in Sotera Health by 14.7% in the 2nd quarter. Texas Permanent School Fund Corp now owns 124,466 shares of the company’s stock worth $1,477,000 after purchasing an additional 15,921 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Sotera Health by 728.0% in the 2nd quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock worth $111,000 after purchasing an additional 8,248 shares during the last quarter. Arizona State Retirement System increased its position in Sotera Health by 45.6% in the 2nd quarter. Arizona State Retirement System now owns 39,589 shares of the company’s stock worth $470,000 after buying an additional 12,404 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in shares of Sotera Health by 25.4% during the second quarter. Victory Capital Management Inc. now owns 25,944 shares of the company’s stock worth $308,000 after buying an additional 5,258 shares during the last quarter. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Sotera Health Stock Performance

Shares of NASDAQ SHC opened at $16.74 on Thursday. The business has a fifty day simple moving average of $14.70 and a 200 day simple moving average of $12.82. The company has a current ratio of 2.93, a quick ratio of 2.59 and a debt-to-equity ratio of 5.46. The firm has a market capitalization of $4.74 billion, a price-to-earnings ratio of 88.11 and a beta of 2.07. Sotera Health has a one year low of $10.71 and a one year high of $17.44.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Monday, August 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.04. The business had revenue of $277.00 million during the quarter, compared to analyst estimates of $266.45 million. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. Sotera Health’s revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.19 earnings per share. Sell-side analysts expect that Sotera Health will post 0.64 EPS for the current year.

Insider Activity at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now directly owns 49,215,301 shares in the company, valued at $739,705,974.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 55.12% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on SHC shares. Barclays increased their price objective on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a research report on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $15.70.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.